why biotech is having a moment!
its not surprising to see a re-rating on life sciences and health stocks in 2024. Investors like strategic advantage, lower capital costs, competition moats and wide addressable markets. Unlike critical raw materials, no one country controls the biotech or medtech supply.
The asx has some very strong performers, several of which are well placed to become globally significant industry leaders, including:
Respiri-up 75% in 12 months
Great to see support from specialist biotech funds into these companies such as Merchant
funds management
Here in Germany, EU retail and sophisticated investors continue to buy into dual-listed asx biotech and medtech companies.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
3.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $61.50M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 76366 | 3.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.9¢ | 365213 | 3 |
View Market Depth
| Last trade - 16.22pm 30/06/2025 (20 minute delay) ? |
| VHL (ASX) Chart |
Day chart unavailable